Deutsches Herzzentrum Muenchen: Coronary Disease trials

The registry lists 27 Coronary Disease studies with Deutsches Herzzentrum Muenchen as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 2 1Phase 4 24No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• NIRS-IVUS to Improve Assessment of Coronary Artery Disease Severity in Patients Referred for Transcatheter Aortic Valve ImplantationStatus unknownNCT04976062
• Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous RevaceptCompletedNCT03312855Phase 2
• ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence TomographyCompletedNCT01594736Phase 4
• Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function TestingStatus unknownNCT01456364Phase 4
• Prospective Randomized Trial On Radiation Dose Estimates Of CT Angiography In Patients Applying Iterative Image Reconstruction Techniques - The PROTECTION V Study -Status unknownNCT01453712Phase 4
• Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial FibrillationTerminatedNCT01352702Phase 4
• Test of Long-Term Safety and Efficacy of Sirolimus-Permanent-Polymer Eluting Stent (Cypher)- and Sirolimus-Polymer-free Eluting Stents (PPS/PFS) Assessed by Optical Coherence TomographyStatus unknownNCT01260558Phase 4
• Test Safety and Efficacy of Zotarolimus- and Everolimus-Eluting Stents (ZES/EES) Assessed by Optical Coherence TomographyStatus unknownNCT01230723Phase 4
• Test Safety of Biodegradable and Permanent Limus-Eluting Stents Assessed by Optical Coherence TomographyCompletedNCT01097434Phase 4
• Test Efficacy of Biodegradable and Permanent Limus-Eluting StentsStatus unknownNCT01068106Phase 4
• Reduced Dose of Unfractionated Heparin in Patients Undergoing PCICompletedNCT00735280Phase 4
• Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A Sequential Scan ProtocolStatus unknownNCT00612092Phase 4
• Prospective Randomized Trial On RadiaTion Dose Estimates Of CT AngIOgraphy In PatieNts Scanned With A 100kV ProtocolStatus unknownNCT00611780Phase 4
• International PRospective Multicenter Study On RadiaTion Dose Estimates Of Coronary CT AngIOgraphy IN Daily PracticeCompletedNCT00610766
• 3 Limus Agent Eluting Stents With Different Polymer CoatingCompletedNCT00598676Phase 4
• Drug-eluting Stents to Treat Unprotected Coronary Left Main DiseaseCompletedNCT00598637Phase 4
• Efficacy Study of Rapamycin- vs. Zotarolimus-Eluting Stents to Reduce Coronary RestenosisCompletedNCT00598533Phase 4
• Rapamycin+Estradiol- vs. Rapamycin-Eluting Stents to Reduce Restenosis (ISAR-PEACE)CompletedNCT00402636Phase 4
• Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary SyndromeCompletedNCT00373451Phase 4
• Rapamycin-Eluting Stents With Different Polymer Coating to Reduce Restenosis (ISAR-TEST-3)CompletedNCT00350454Phase 4
• The Efficacy of Three Different Limus Agent-Eluting Stents to Prevent RestenosisCompletedNCT00332397Phase 4
• Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)CompletedNCT00262054Phase 4
• Sirolimus- and Paclitaxel-Eluting Stents for Small Vessels (ISAR-SMART-3)CompletedNCT00146575Phase 4
• Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)CompletedNCT00140530Phase 4
• 75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)CompletedNCT00140465Phase 4
• Drug-eluting-stents for Unprotected Left Main Stem Disease (ISAR-LEFT-MAIN)CompletedNCT00133237Phase 4
• Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)CompletedNCT00133003Phase 4